JPH09507054A - 新規な酵素阻害剤、その合成及び使用方法 - Google Patents
新規な酵素阻害剤、その合成及び使用方法Info
- Publication number
- JPH09507054A JPH09507054A JP7513211A JP51321195A JPH09507054A JP H09507054 A JPH09507054 A JP H09507054A JP 7513211 A JP7513211 A JP 7513211A JP 51321195 A JP51321195 A JP 51321195A JP H09507054 A JPH09507054 A JP H09507054A
- Authority
- JP
- Japan
- Prior art keywords
- phenylselenyl
- methyl
- hydroxyethoxy
- phenylthio
- uracil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 35
- 230000015572 biosynthetic process Effects 0.000 title description 18
- 238000003786 synthesis reaction Methods 0.000 title description 16
- 239000002532 enzyme inhibitor Substances 0.000 title description 7
- 229940125532 enzyme inhibitor Drugs 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 113
- -1 methoxy, benzyl Chemical group 0.000 claims abstract description 55
- 108010019092 Uridine phosphorylase Proteins 0.000 claims abstract description 51
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 48
- 229940127089 cytotoxic agent Drugs 0.000 claims abstract description 47
- 102000004190 Enzymes Human genes 0.000 claims abstract description 43
- 108090000790 Enzymes Proteins 0.000 claims abstract description 43
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 33
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims abstract description 30
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 25
- 201000011510 cancer Diseases 0.000 claims abstract description 21
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 17
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 10
- 125000001544 thienyl group Chemical group 0.000 claims abstract description 9
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims description 115
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims description 58
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 claims description 56
- 229940045145 uridine Drugs 0.000 claims description 56
- 239000003112 inhibitor Substances 0.000 claims description 49
- 102000006405 Uridine phosphorylase Human genes 0.000 claims description 45
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 33
- 239000002718 pyrimidine nucleoside Substances 0.000 claims description 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 17
- 229940002612 prodrug Drugs 0.000 claims description 17
- 239000000651 prodrug Substances 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 16
- 229940035893 uracil Drugs 0.000 claims description 16
- 241000233866 Fungi Species 0.000 claims description 14
- 241000700605 Viruses Species 0.000 claims description 14
- 241000894006 Bacteria Species 0.000 claims description 13
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims description 12
- GUUVPOWQJOLRAS-UHFFFAOYSA-N Diphenyl disulfide Chemical compound C=1C=CC=CC=1SSC1=CC=CC=C1 GUUVPOWQJOLRAS-UHFFFAOYSA-N 0.000 claims description 10
- 231100000419 toxicity Toxicity 0.000 claims description 10
- 230000001988 toxicity Effects 0.000 claims description 10
- MFORXTHLVUSZNY-UHFFFAOYSA-N 5-phenylsulfanyl-1h-pyrimidine-2,4-dione Chemical compound O=C1NC(=O)NC=C1SC1=CC=CC=C1 MFORXTHLVUSZNY-UHFFFAOYSA-N 0.000 claims description 9
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 9
- ZEGGHGSNGZPEHQ-UHFFFAOYSA-N 5-phenylselanyl-1h-pyrimidine-2,4-dione Chemical compound O=C1NC(=O)NC=C1[Se]C1=CC=CC=C1 ZEGGHGSNGZPEHQ-UHFFFAOYSA-N 0.000 claims description 8
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 8
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 8
- WFWLQNSHRPWKFK-UHFFFAOYSA-N Tegafur Chemical compound O=C1NC(=O)C(F)=CN1C1OCCC1 WFWLQNSHRPWKFK-UHFFFAOYSA-N 0.000 claims description 8
- 229960002949 fluorouracil Drugs 0.000 claims description 8
- 230000001575 pathological effect Effects 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- GQERGAYPZWJSAF-UHFFFAOYSA-N 1-(2-hydroxyethoxymethyl)-5-phenylselanyl-1,3-diazinane-2,4,6-trione Chemical compound O=C1N(COCCO)C(=O)NC(=O)C1[Se]C1=CC=CC=C1 GQERGAYPZWJSAF-UHFFFAOYSA-N 0.000 claims description 7
- KFSPSGWABMNFIY-UHFFFAOYSA-N 1-(2-hydroxyethoxymethyl)-5-phenylselanylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)N(COCCO)C=C1[Se]C1=CC=CC=C1 KFSPSGWABMNFIY-UHFFFAOYSA-N 0.000 claims description 7
- KFRZFMXZIDRZJI-UHFFFAOYSA-N 5-phenylselanyl-1,3-diazinane-2,4,6-trione Chemical compound O=C1NC(=O)NC(=O)C1[Se]C1=CC=CC=C1 KFRZFMXZIDRZJI-UHFFFAOYSA-N 0.000 claims description 6
- KRPWRQUISWCMBL-UHFFFAOYSA-N 5-phenylsulfanyl-1,3-diazinane-2,4,6-trione Chemical compound O=C1NC(=O)NC(=O)C1SC1=CC=CC=C1 KRPWRQUISWCMBL-UHFFFAOYSA-N 0.000 claims description 6
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 6
- YWWZCHLUQSHMCL-UHFFFAOYSA-N diphenyl diselenide Chemical compound C=1C=CC=CC=1[Se][Se]C1=CC=CC=C1 YWWZCHLUQSHMCL-UHFFFAOYSA-N 0.000 claims description 6
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 claims description 6
- 229940127073 nucleoside analogue Drugs 0.000 claims description 6
- YWJXYUXIPSIOGG-UHFFFAOYSA-N 1-((2-hydroxyethoxy)methyl)-5-(phenylthio)pyrimidine-2,4(1h,3h)-dione Chemical compound O=C1NC(=O)N(COCCO)C=C1SC1=CC=CC=C1 YWJXYUXIPSIOGG-UHFFFAOYSA-N 0.000 claims description 5
- ZSNNBSPEFVIUDS-SHYZEUOFSA-N 1-[(2r,4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound C1[C@H](N=[N+]=[N-])[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 ZSNNBSPEFVIUDS-SHYZEUOFSA-N 0.000 claims description 5
- QBEIABZPRBJOFU-CAHLUQPWSA-N 4-amino-5-fluoro-1-[(2r,5s)-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound C1=C(F)C(N)=NC(=O)N1[C@@H]1O[C@H](CO)CC1 QBEIABZPRBJOFU-CAHLUQPWSA-N 0.000 claims description 5
- UXCAQJAQSWSNPQ-XLPZGREQSA-N Alovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](F)C1 UXCAQJAQSWSNPQ-XLPZGREQSA-N 0.000 claims description 5
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 claims description 5
- JTEGQNOMFQHVDC-RQJHMYQMSA-N 4-amino-1-[(2s,5r)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)SC1 JTEGQNOMFQHVDC-RQJHMYQMSA-N 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 230000010076 replication Effects 0.000 claims description 4
- PMRHGPAHIQRUBY-UHFFFAOYSA-N 2,4-bis(phenylmethoxy)-5-phenylselanylpyrimidine Chemical compound C=1C=CC=CC=1COC(N=C1OCC=2C=CC=CC=2)=NC=C1[Se]C1=CC=CC=C1 PMRHGPAHIQRUBY-UHFFFAOYSA-N 0.000 claims description 3
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000003834 intracellular effect Effects 0.000 claims description 3
- 230000004962 physiological condition Effects 0.000 claims description 3
- 239000007858 starting material Substances 0.000 claims description 3
- PJFNWHZWZAJIND-UHFFFAOYSA-N 1-(ethoxymethyl)-5-phenylselanylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)N(COCC)C=C1[Se]C1=CC=CC=C1 PJFNWHZWZAJIND-UHFFFAOYSA-N 0.000 claims description 2
- DVGDDZUHRSIGQR-UHFFFAOYSA-N 2,4-bis(phenylmethoxy)-5-phenylsulfanylpyrimidine Chemical compound C=1C=CC=CC=1COC(N=C1OCC=2C=CC=CC=2)=NC=C1SC1=CC=CC=C1 DVGDDZUHRSIGQR-UHFFFAOYSA-N 0.000 claims description 2
- LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 claims description 2
- 230000037041 intracellular level Effects 0.000 claims description 2
- 230000002194 synthesizing effect Effects 0.000 claims description 2
- UTKBQCBAMCEBTL-UHFFFAOYSA-N 1-(2-hydroxyethoxymethyl)-5-phenylsulfanyl-1,3-diazinane-2,4,6-trione Chemical compound O=C1N(COCCO)C(=O)NC(=O)C1SC1=CC=CC=C1 UTKBQCBAMCEBTL-UHFFFAOYSA-N 0.000 claims 6
- OUAPULXYUWUOHW-UHFFFAOYSA-N 1-(ethoxymethyl)-5-fluoropyrimidine-2,4-dione Chemical compound CCOCN1C=C(F)C(=O)NC1=O OUAPULXYUWUOHW-UHFFFAOYSA-N 0.000 claims 3
- XQSPYNMVSIKCOC-RITPCOANSA-N 4-amino-5-fluoro-1-[(2s,5r)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one Chemical compound C1=C(F)C(N)=NC(=O)N1[C@@H]1O[C@H](CO)SC1 XQSPYNMVSIKCOC-RITPCOANSA-N 0.000 claims 3
- 244000045947 parasite Species 0.000 claims 3
- LLEDHRMCLYPYKR-DMDPSCGWSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-phenylselanylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C([Se]C=2C=CC=CC=2)=C1 LLEDHRMCLYPYKR-DMDPSCGWSA-N 0.000 claims 2
- STBPEGOCUIKHIM-UHFFFAOYSA-N 5-phenylmethoxy-1,3-diazinane-2,4,6-trione Chemical compound O=C1NC(=O)NC(=O)C1OCC1=CC=CC=C1 STBPEGOCUIKHIM-UHFFFAOYSA-N 0.000 claims 2
- ALJMTFKADFATPR-UHFFFAOYSA-N 1-(ethoxymethyl)-5-phenylselanyl-1,3-diazinane-2,4,6-trione Chemical compound O=C1N(COCC)C(=O)NC(=O)C1[Se]C1=CC=CC=C1 ALJMTFKADFATPR-UHFFFAOYSA-N 0.000 claims 1
- JAHLFAWFOKQUDC-DMDPSCGWSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-phenylsulfanylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(SC=2C=CC=CC=2)=C1 JAHLFAWFOKQUDC-DMDPSCGWSA-N 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- HBEXQFKVNOXMOD-UHFFFAOYSA-M sodium;2-hydroxy-2,2-diphenylacetate Chemical compound [Na+].C=1C=CC=CC=1C(C([O-])=O)(O)C1=CC=CC=C1 HBEXQFKVNOXMOD-UHFFFAOYSA-M 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 23
- 230000015556 catabolic process Effects 0.000 abstract description 19
- 238000011282 treatment Methods 0.000 abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 16
- 208000030852 Parasitic disease Diseases 0.000 abstract description 11
- 230000001580 bacterial effect Effects 0.000 abstract description 6
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 5
- 208000035143 Bacterial infection Diseases 0.000 abstract description 4
- 208000022362 bacterial infectious disease Diseases 0.000 abstract description 4
- 230000002538 fungal effect Effects 0.000 abstract description 3
- 206010017533 Fungal infection Diseases 0.000 abstract description 2
- 208000031888 Mycoses Diseases 0.000 abstract description 2
- 238000003384 imaging method Methods 0.000 abstract description 2
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
- 108010088106 Dihydrouracil Dehydrogenase (NAD+) Proteins 0.000 description 36
- 102100022334 Dihydropyrimidine dehydrogenase [NADP(+)] Human genes 0.000 description 34
- 150000003230 pyrimidines Chemical class 0.000 description 20
- 238000002512 chemotherapy Methods 0.000 description 15
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 231100000331 toxic Toxicity 0.000 description 11
- 230000002588 toxic effect Effects 0.000 description 11
- 229910001868 water Inorganic materials 0.000 description 11
- 238000005160 1H NMR spectroscopy Methods 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 10
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 10
- 229910052799 carbon Inorganic materials 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 229910052739 hydrogen Inorganic materials 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 239000002777 nucleoside Substances 0.000 description 9
- 230000036470 plasma concentration Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 8
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 8
- 238000006731 degradation reaction Methods 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 7
- 229940000635 beta-alanine Drugs 0.000 description 7
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene chloride Substances ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 229940104230 thymidine Drugs 0.000 description 7
- OIVLITBTBDPEFK-UHFFFAOYSA-N 5,6-dihydrouracil Chemical compound O=C1CCNC(=O)N1 OIVLITBTBDPEFK-UHFFFAOYSA-N 0.000 description 6
- 208000024827 Alzheimer disease Diseases 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 238000004809 thin layer chromatography Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 6
- 230000000840 anti-viral effect Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 150000003833 nucleoside derivatives Chemical class 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 206010067125 Liver injury Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010039966 Senile dementia Diseases 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000001925 catabolic effect Effects 0.000 description 3
- 208000015114 central nervous system disease Diseases 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- 210000000172 cytosol Anatomy 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 3
- 231100000234 hepatic damage Toxicity 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000008818 liver damage Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- WJCXADMLESSGRI-UHFFFAOYSA-N phenyl selenohypochlorite Chemical compound Cl[Se]C1=CC=CC=C1 WJCXADMLESSGRI-UHFFFAOYSA-N 0.000 description 3
- 229910000160 potassium phosphate Inorganic materials 0.000 description 3
- 235000011009 potassium phosphates Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- ISAKRJDGNUQOIC-HQMMCQRPSA-N (614C)1H-pyrimidine-2,4-dione Chemical compound N1C(=O)NC(=O)C=[14CH]1 ISAKRJDGNUQOIC-HQMMCQRPSA-N 0.000 description 2
- YDYOYUPJKSJCMF-UHFFFAOYSA-N 1-(2-hydroxyethoxymethyl)pyrimidine-2,4-dione Chemical class OCCOCN1C=CC(=O)NC1=O YDYOYUPJKSJCMF-UHFFFAOYSA-N 0.000 description 2
- AXVSENOQDLPSLQ-XVKPBYJWSA-N 1-[(2s,5s)-2-amino-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@]1(N)O[C@H](CO)CC1 AXVSENOQDLPSLQ-XVKPBYJWSA-N 0.000 description 2
- SPJAGILXQBHHSZ-UHFFFAOYSA-N 5-benzyl-1-(2-hydroxyethoxymethyl)uracil Chemical compound O=C1NC(=O)N(COCCO)C=C1CC1=CC=CC=C1 SPJAGILXQBHHSZ-UHFFFAOYSA-N 0.000 description 2
- ZNLSBGQCJIWHCT-UHFFFAOYSA-N 6-phenylsulfanyl-1h-pyrimidine-2,4-dione Chemical compound N1C(=O)NC(=O)C=C1SC1=CC=CC=C1 ZNLSBGQCJIWHCT-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- JSJWCHRYRHKBBW-UHFFFAOYSA-N N-carbamoyl-beta-alanine Chemical compound NC(=O)NCCC(O)=O JSJWCHRYRHKBBW-UHFFFAOYSA-N 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000009097 Phosphorylases Human genes 0.000 description 2
- 108010073135 Phosphorylases Proteins 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 229940045688 antineoplastic antimetabolites pyrimidine analogues Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 150000001576 beta-amino acids Chemical class 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- 125000006267 biphenyl group Chemical group 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 230000006652 catabolic pathway Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 239000007958 cherry flavor Substances 0.000 description 2
- 230000027288 circadian rhythm Effects 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000007337 electrophilic addition reaction Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 230000004190 glucose uptake Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 229910052727 yttrium Inorganic materials 0.000 description 2
- UNRYGRHRRHNWHF-UHFFFAOYSA-N 1-(ethoxymethyl)pyrimidine-2,4-dione Chemical compound CCOCN1C=CC(=O)NC1=O UNRYGRHRRHNWHF-UHFFFAOYSA-N 0.000 description 1
- XKKCQTLDIPIRQD-JGVFFNPUSA-N 1-[(2r,5s)-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)CC1 XKKCQTLDIPIRQD-JGVFFNPUSA-N 0.000 description 1
- RXFGNZUKBIJUON-UHFFFAOYSA-N 2,4-bis(phenylmethoxy)-6-phenylselanylpyrimidine Chemical compound C=1C=CC=CC=1COC(N=C(OCC=1C=CC=CC=1)N=1)=CC=1[Se]C1=CC=CC=C1 RXFGNZUKBIJUON-UHFFFAOYSA-N 0.000 description 1
- CAVAKZBRZJXJPP-UHFFFAOYSA-N 2,4-bis(phenylmethoxy)-6-phenylsulfanylpyrimidine Chemical compound C=1C=CC=CC=1COC(N=C(OCC=1C=CC=CC=1)N=1)=CC=1SC1=CC=CC=C1 CAVAKZBRZJXJPP-UHFFFAOYSA-N 0.000 description 1
- PXQPEWDEAKTCGB-YZRHJBSPSA-N 2,4-dioxo-(414C)1H-pyrimidine-6-carboxylic acid Chemical compound C(C1=C[14C](=O)NC(=O)N1)(=O)O PXQPEWDEAKTCGB-YZRHJBSPSA-N 0.000 description 1
- LASFZUMWPDIASP-UHFFFAOYSA-N 3-(fluoroamino)propanoic acid Chemical compound OC(=O)CCNF LASFZUMWPDIASP-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- SGCSNJNPPSSPKZ-UHFFFAOYSA-N 5-bromo-2,4-dichloropyridine Chemical compound ClC1=CC(Cl)=C(Br)C=N1 SGCSNJNPPSSPKZ-UHFFFAOYSA-N 0.000 description 1
- OQRXBXNATIHDQO-UHFFFAOYSA-N 6-chloropyridine-3,4-diamine Chemical compound NC1=CN=C(Cl)C=C1N OQRXBXNATIHDQO-UHFFFAOYSA-N 0.000 description 1
- CARVSBLQJFFLHY-UHFFFAOYSA-N 6-phenylselanyl-1h-pyrimidine-2,4-dione Chemical compound N1C(=O)NC(=O)C=C1[Se]C1=CC=CC=C1 CARVSBLQJFFLHY-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- XTFRFKGLWRRAQS-UHFFFAOYSA-N C(C)OCC1=C(C(NC(N1)=O)=O)F Chemical compound C(C)OCC1=C(C(NC(N1)=O)=O)F XTFRFKGLWRRAQS-UHFFFAOYSA-N 0.000 description 1
- VCFMRAHMPIHKBY-ZOWXZIJZSA-N C1(=CC=CC=C1)[C@@]1(C[C@H](O)[C@@H](CO)O1)N1C(=S)NC(=O)C=C1 Chemical compound C1(=CC=CC=C1)[C@@]1(C[C@H](O)[C@@H](CO)O1)N1C(=S)NC(=O)C=C1 VCFMRAHMPIHKBY-ZOWXZIJZSA-N 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 102100036238 Dihydropyrimidinase Human genes 0.000 description 1
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- 101000783356 Naja sputatrix Cytotoxin Proteins 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000036848 Porzana carolina Species 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102100036286 Purine nucleoside phosphorylase Human genes 0.000 description 1
- 102000001853 Pyrimidine Phosphorylases Human genes 0.000 description 1
- 108010054917 Pyrimidine Phosphorylases Proteins 0.000 description 1
- 101710132082 Pyrimidine/purine nucleoside phosphorylase Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 102000013537 Thymidine Phosphorylase Human genes 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- MWOBKFYERIDQSZ-UHFFFAOYSA-N benzene;sodium Chemical compound [Na].C1=CC=CC=C1 MWOBKFYERIDQSZ-UHFFFAOYSA-N 0.000 description 1
- 239000003858 bile acid conjugate Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002340 cardiotoxin Substances 0.000 description 1
- 231100000677 cardiotoxin Toxicity 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 231100000359 cholestasis Toxicity 0.000 description 1
- 230000007870 cholestasis Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 108091022884 dihydropyrimidinase Proteins 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- XIMIGUBYDJDCKI-UHFFFAOYSA-N diselenium Chemical compound [Se]=[Se] XIMIGUBYDJDCKI-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 150000005699 fluoropyrimidines Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- UQEAIHBTYFGYIE-UHFFFAOYSA-N hexamethyldisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)C UQEAIHBTYFGYIE-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 238000006138 lithiation reaction Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- GMDNUWQNDQDBNQ-UHFFFAOYSA-L magnesium;diformate Chemical compound [Mg+2].[O-]C=O.[O-]C=O GMDNUWQNDQDBNQ-UHFFFAOYSA-L 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 238000004452 microanalysis Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 108010009099 nucleoside phosphorylase Proteins 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- LFQULJPVXNYWAG-UHFFFAOYSA-N sodium;phenylmethanolate Chemical compound [Na]OCC1=CC=CC=C1 LFQULJPVXNYWAG-UHFFFAOYSA-N 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 235000015041 whisky Nutrition 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 一般式 {ここで、XはS又はSeであり、YはI、F、Cl、Br、メトキシ、ベンジ ル、セレニルフェニル又はチオフェニルであり、R1は一般式 (ここで、R2はH、CH2OH又はCH2NH2であり、R3はOH、NH2又はO COCH2CH2CO2Hであり、R4はO、S又はCH2である) を有するアシクロ末端である} によって表わされる化合物。 2. 5−(フェニルセレニル)ウラシル(PSU)である請求の範囲1記載の 化合物。 3. 1−[(2−ヒドロキシエトキシ)メチル]−5−(フェニルセレニル) ウラシル(PSAU)である請求の範囲1記載の化合物。 4. 5−(フェニルセレニル)−2,4−ビス(ベン ジルオキシ)ピリミジンである請求の範囲1記載の化合物。 5. 1−(エトキシメチル)−5−(フェニルセレニル)ウラシルである請求 の範囲1記載の化合物。 6. 5−(フェニルチオ)ウラシル(PTU)である請求の範囲1記載の化合 物。 7. 1−[(2−ヒドロキシエトキシ)メチル]−5−(フェニルチオ)ウラ シル(PTAU)である請求の範囲1記載の化合物。 8. 5−(フェニルチオ)−2,4−ビス(ベンジルオキシ)ピリミジンであ る請求の範囲1記載の化合物。 9. 5−(フェニルセレニル)バルビツル酸である請求の範囲1記載の化合物 。 10. 1−[(2−ヒドロキシエトキシ)メチル]−5−(フェニルセレニル )バルビツル酸である請求の範囲1記載の化合物。 11. 5−(フェニルセレニル)−2,4−ビス(ベンジルオキシ)バルビツ ル酸である請求の範囲1記載の化合物。 12. 1−(エトキシメチル)−5−(フェニルセレニル)バルビツル酸であ る請求の範囲1記載の化合物。 13. 5−(フェニルチオ)バルビツル酸である請求の範囲1記載の化合物。 14. 1−[(2−ヒドロキシエトキシ)メチル]−5−(フェニルチオ)バ ルビツル酸である請求の範囲1記載の化合物。 15. 5−(フェニルチオ)−2,4−ビス(ベンジルオキシ)バルビツル酸 である請求の範囲1記載の化合物。 16. 下記の成分 (a)ウイルス、癌、菌類、寄生生物又は細菌の複製を破壊させるのに有効な量 のピリミジン化合物、 (b)一般式 {ここで、XはS又はSeであり、YはI、F、Cl、Br、メトキシ、ベンジ ル、セレニルフェニル又はチオフェニルであり、R1は一般式 (ここで、R2はH、CH2OH又はCH2NH2であり、R3はOH、NH2又はO COCH2CH2CO2Hであり、R4はO、S又はCH2である) を有するアシクロ末端である} によって表わされる化合物、及び (c)製薬上許容できるキャリアー を含む製薬組成物。 17. ピリミジン化合物がピリミジン核塩基類似体、ピリミジン核塩基類似体 のプロドラッグ、ピリミジンヌクレオシド類似体、ピリミジンヌクレオシド類似 体のプロドラッグ、これらのヘテロ二量体及びこれらのエナンチオマーよりなる 群から選択される請求の範囲16記載の組成物。 18. ピリミジン化合物が3’−アジド−3’−デオキシチミジン、3’−フ ルオル−3’−デオキシチミジン、2’,3’−ジデオキシシチジン−2’−エ ン、3’−デオキシチミジン−2’−エン、3’−アジド−2’,3’−ジデオ キシウリジン、2’,3’−ジデオキシ−5−フルオル−3’−チアシチジン、 2’,3’−ジデオキシ−3’−チアシチジン、5−フルオル−2’,3’−ジ デオキシシチジン、5−フルオルウラシル、5−フルオル−2’−デオキシウリ ジン、1−(テトラヒドロフリル)−5−フルオルウラシル、5−フルオルシト シン、5’−デオキシ−5−フルオルウリジン、1−エトキシメチル−5−フル オルウラシル、これらのヘテロ二量体及びこれらのエナンチオマーよりなる群か ら選択される請求の範囲17記載の組成物。 19. 酵素阻害化合物がDHUDアーゼを阻害するものであって、5−(フェ ニルセレニル)ウラシル、5− (フェニルチオ)ウラシル、5−(フェニルセレニル)バルビツル酸及び5−( フェニルチオ)バルビツル酸よりなる群から選択される請求の範囲16記載の組 成物。 20. 酵素阻害化合物がUrdPアーゼを阻害するものであって、1−[(2 −ヒドロキシエトキシ)メチル]−5−(フェニルセレニル)ウラシル、1−[ (2−ヒドロキシエトキシ)メチル]−5−(フェニルチオ)ウラシル、1−[ (2−ヒドロキシエトキシ)メチル]−5−(フェニルセレニル)バルビツル酸 及び1−[(2−ヒドロキシエトキシ)メチル]−5−(フェニルチオ)バルビ ツル酸よりなる群から選択される請求の範囲16記載の組成物。 21. 化学療法剤の投与により生じる毒性から正常な又は未感染の細胞を保護 し及び(又は)救済する方法であって、 ウイルス、癌、菌類、細菌又は寄生生物の複製を破壊させるのに有効な化学療 法剤を投与し、 DHUDアーゼ又はUrdPアーゼを阻害させるのに有効な量の、一般式 {ここで、XはS又はSeであり、YはI、F、Cl、Br、メトキシ、ベンジ ル、セレニルフェニル又はチオフェニルであり、R1は一般式 (ここで、R2はH、CH2OH又はCH2NH2であり、R3はOH、NH2又はO COCH2CH2CO2Hであり、R4はO、S又はCH2である) を有するアシクロ末端である} によって表わされる酵素阻害化合物を同時に投与し又は逐次的に投与する ことからなる前記の方法。 22. 化学療法剤がピリミジン核塩基類似体、ピリミジン核塩基類似体のプロ ドラッグ、ピリミジンヌクレオシド類似体、ピリミジンヌクレオシド類似体のプ ロドラッグ、これらのヘテロ二量体及びこれらのエナンチオマーよりなる群から 選択される請求の範囲21記載の方法。 23. 化学療法剤が3’−アジド−3’−デオキシチミジン、3’−フルオル −3’−デオキシチミジン、2’,3’−ジデオキシシチジン−2’−エン、3 ’−デオキシチミジン−2’−エン、3’−アジド−2’,3’−ジデオキシウ リジン、2’,3’−ジデオキシ−5−フルオル−3’−チアシチジン、2’, 3’−ジデ オキシ−3’−チアシチジン、5−フルオル−2’,3’−ジデオキシシチジン 、5−フルオルウラシル、5−フルオル−2’−デオキシウリジン、1−(テト ラヒドロフリル)−5−フルオルウラシル、5−フルオルシトシン、5’−デオ キシ−5−フルオルウリジン、1−エトキシメチル−5−フルオルウラシル、こ れらのヘテロ二量体及びこれらのエナンチオマーよりなる群から選択される請求 の範囲22記載の方法。 24. 酵素阻害化合物がDHUDアーゼを阻害するものであって、5−(フェ ニルセレニル)ウラシル、5−(フェニルチオ)ウラシル、5−(フェニルセレ ニル)バルビツル酸及び5−(フェニルチオ)バルビツル酸よりなる群から選択 される請求の範囲21記載の方法。 25. 酵素阻害化合物がウリジンホスホリラーゼを阻害するものであって、1 −[(2−ヒドロキシエトキシ)メチル]−5−(フェニルセレニル)ウラシル 、1−[(2−ヒドロキシエトキシ)メチル]−5−(フェニルチオ)ウラシル 、1−[(2−ヒドロキシエトキシ)メチル]−5−(フェニルセレニル)バル ビツル酸及び1−[(2−ヒドロキシエトキシ)メチル]−5−(フェニルチオ )バルビツル酸よりなる群から選択される請求の範囲21記載の方法。 26. 酵素阻害化合物が約5〜約500mg/kg/日の薬量で投与される請 求の範囲21記載の方法。 27. 化学療法剤の投与により生じる毒性から正常な 又は未感染の細胞を保護し及び(又は)救済する方法であって、 ウイルス、癌、菌類、細菌又は寄生生物の複製を破壊させるのに有効な量の化 学療法剤を投与し、 1−[(2−ヒドロキシエトキシ)メチル]−5−(フェニルセレニル)ウラ シル、1−[(2−ヒドロキシエトキシ)メチル]−5−(フェニルチオ)ウラ シル、1−[(2−ヒドロキシエトキシ)メチル]−5−(フェニルセレニル) バルビツル酸、1−[(2−ヒドロキシエトキシ)メチル]−5−(フェニルチ オ)バルビツル酸、5−(フェニルセレニル)ウリジン、5−(フェニルセレニ ル)−2’−デオキシウリジン、1−[(2−ヒドロキシエトキシ)メチル]− 6−(フェニルセレニル)ウリジン、5−(フェニルチオ)ウリジン、5−(フ ェニルチオ)−2’−デオキシウリジン、1−[(2−ヒドロキシエトキシ)メ チル]−6−(フェニルチオ)ウリジン、1−[(2−ヒドロキシエトキシ)メ チル]−6−(フェニルセレニル)バルビツル酸及び1−[(2−ヒドロキシエ トキシ)メチル]−6−(フェニルチオ)バルビツル酸よりなる群から選択され るUrdPアーゼ阻害化合物を約5〜200mg/kg/日の薬量で同時に投与 し又は逐次的に投与する ことからなる前記の方法。 28. ピリミジン塩基又はピリミジンヌクレオシド治療剤の効能を向上させる 方法であって、 ピリミジン塩基又はピリミジンヌクレオシド治療剤を投与し、 一般式 {ここで、XはS又はSeであり、YはI、F、Cl、Br、メトキシ、ベンジ ル、セレニルフェニル又はチオフェニルであり、R1は一般式 (ここで、R2はH、CH2OH又はCH2NH2であり、R3はOH、NH2又はO COCH2CH2CO2Hであり、R4はO、S又はCH2である) を有するアシクロ末端である} によって表わされる酵素阻害化合物を同時に投与し又は逐次的に投与する ことからなる前記の方法。 29. 治療剤がピリミジン核塩基類似体、ピリミジン核塩基類似体のプロドラ ッグ、ピリミジンヌクレオシド類似体、ピリミジンヌクレオシド類似体のプロド ラッグ、これらのヘテロ二量体及びこれらのエナンチオマーよ りなる群から選択される請求の範囲28記載の方法。 30. 治療剤が3’−アジド−3’−デオキシチミジン、3’−フルオル−3 ’−デオキシチミジン、2’,3’−ジデオキシシチジン−2’−エン、3’− デオキシチミジン−2’−エン、3’−アジド−2’,3’ジデオキシウリジン 、2’,3’−ジデオキシ−5−フルオル−3’−チアシチジン、2’,3’− ジデオキシ−3’−チアシチジン、5−フルオル−2’,3’−ジデオキシシチ ジン、5−フルオルウラシル、5−フルオル−2’−デオキシウリジン、1−( テトラヒドロフリル)−5−フルオルウラシル、5−フルオルシトシン、5’− デオキシ−5−フルオルウリジン、1−エトキシメチル−5−フルオルウラシル 、これらのヘテロ二量体及びこれらのエナンチオマーよりなる群から選択される 請求の範囲29記載の方法。 31. 酵素阻害化合物がDHUDアーゼを阻害するものであって、5−(フェ ニルセレニル)ウラシル、5−(フェニルチオ)ウラシル、5−(フェニルセレ ニル)バルビツル酸及び5−(フェニルチオ)バルビツル酸よりなる群から選択 される請求の範囲28記載の方法。 32. 酵素阻害化合物がUrdPアーゼを阻害するものであって、1−[(2 −ヒドロキシエトキシ)メチル]−5−(フェニルセレニル)ウラシル、1−[ (2−ヒドロキシエトキシ)メチル]−5−(フェニルチオ)ウラシル、1−[ (2−ヒドロキシエトキシ)メチル] −5−(フェニルセレニル)バルビツル酸及び1−[(2−ヒドロキシエトキシ )メチル]−5−(フェニルチオ)バルビツル酸よりなる群から選択される請求 の範囲28記載の方法。 33. 酵素阻害化合物が約5〜約500mg/kg/日の薬量で投与される請 求の範囲28記載の方法。 34. ピリミジン塩基又はピリミジンヌクレオシド治療剤の効能を向上させる 方法であって、 ピリミジン塩基又はピリミジンヌクレオシド治療剤を投与し、 1−[(2−ヒドロキシエトキシ)メチル]−5−(フェニルセレニル)ウラ シル、1−[(2−ヒドロキシエトキシ)メチル]−5−(フェニルチオ)ウラ シル、1−[(2−ヒドロキシエトキシ)メチル]−5−(フェニルセレニル) バルビツル酸、1−[(2−ヒドロキシエトキシ)メチル]−5−(フェニルチ オ)バルビツル酸、5−(フェニルセレニル)ウリジン、5−(フェニルセレニ ル)−2’−デオキシウリジン、1−[(2−ヒドロキシエトキシ)メチル]− 6−(フェニルセレニル)ウリジン、5−(フェニルチオ)ウリジン、5−(フ ェニルチオ)−2’−デオキシウリジン、1−[(2−ヒドロキシエトキシ)メ チル]−6−(フェニルチオ)ウリジン、1−[(2−ヒドロキシエトキシ)メ チル]−6−(フェニルセレニル)バルビツル酸及び1−[(2−ヒドロキシエ トキシ)メチル]−6−(フェニ ルチオ)バルビツル酸よりなる群から選択されるUrdPアーゼ阻害化合物を約 5〜500mg/kg/日の薬量で同時に投与し又は逐次的に投与する ことからなる前記の方法。 35. 増大したピリミジンレベルに有利に応答する病理学的又は生理学的な状 態を処置するためにピリミジンの細胞内レベルを増大させるにあたり、患者に一 般式 {ここで、XはS又はSeであり、YはI、F、Cl、Br、メトキシ、ベンジ ル、セレニルフェニル又はチオフェニルであり、R1は一般式 (ここで、R2はH、CH2OH又はCH2NH2であり、R3はOH、NH2又はO COCH2CH2CO2Hであり、R4はO、S又はCH2である) を有するアシクロ末端である} によって表わされる化合物を、患者の細胞内ピリミジンレベルを増大させるのに 有効な量で投与することからなる、ピリミジンの細胞内レベルを増大させる方法 。 36. 5−ブロムウラシル出発化合物を用意し、 この出発化合物を化学量論的に過剰量のPOCl3と反応させて塩素化ブロム ピリミジン化合物を得、 塩素化ブロムピリミジン化合物をナトリウムベンジラートで処理してベンジル オキシ化合物を得、 ベンジルオキシ化合物をリチウム化してリチウム化生成物となし、 リチウム化生成物をジフェニルジセレニド又はジフェニルジスルフィドと反応 させて2及び4位にベンジルオキシ保護基を有するヘテラフェニルピリミジンを 得、 このベンジル基を解裂させて5−ヘテラフェニルウラシル目的生成物を得る ことからなる5−ヘテラフェニルウラシル化合物を合成する方法。 37. リチウム化生成物をジフェニルジセレニドと反応させ、それによって得 られる目的生成物が5−(フェニルセレニル)ウラシルである請求の範囲36記 載の方法。 38. リチウム化生成物をジフェニルジスルフィドと反応させ、それによって 得られる目的生成物が5−(フェニルチオ)ウラシルである請求の範囲36記載 の方法。 39. 一般式 {ここで、XはS又はSeであり、YはI、F、Cl、Br、メトキシ、ベンジ ル、セレニルフェニル又はチオフェニルであり、R1は一般式 (ここで、R2はH、CH2OH又はCH2NH2であり、R3はOH、NH2又はO COCH2CH2CO2Hであり、R4はO、S又はCH2である) を有するアシクロ末端である} によって表わされる化合物、及び 製薬上許容できるキャリアー を含む製薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/146,838 US5476855A (en) | 1993-11-02 | 1993-11-02 | Enzyme inhibitors, their synthesis and methods for use |
US08/146,838 | 1993-11-02 | ||
PCT/US1994/011173 WO1995012400A1 (en) | 1993-11-02 | 1994-09-30 | Novel enzyme inhibitors, their synthesis, and methods for use |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09507054A true JPH09507054A (ja) | 1997-07-15 |
JP3621102B2 JP3621102B2 (ja) | 2005-02-16 |
Family
ID=22519188
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51321195A Expired - Fee Related JP3621102B2 (ja) | 1993-11-02 | 1994-09-30 | 新規な酵素阻害剤、その合成及び使用方法 |
Country Status (9)
Country | Link |
---|---|
US (3) | US5476855A (ja) |
EP (1) | EP0725641B1 (ja) |
JP (1) | JP3621102B2 (ja) |
AT (1) | ATE198046T1 (ja) |
AU (1) | AU699914B2 (ja) |
DE (1) | DE69426423T2 (ja) |
ES (1) | ES2155093T3 (ja) |
PT (1) | PT725641E (ja) |
WO (1) | WO1995012400A1 (ja) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5476855A (en) * | 1993-11-02 | 1995-12-19 | Mahmoud H. el Kouni | Enzyme inhibitors, their synthesis and methods for use |
JP2683297B2 (ja) * | 1994-02-28 | 1997-11-26 | スンキョン インダストリーズ カンパニー リミテッド | ピリミジンアシクロヌクレオシド誘導体 |
US5811073A (en) * | 1995-06-19 | 1998-09-22 | President And Fellows Of Harvard College | Method for radioisotopic detection and localization of inflammation in a host |
US5719132A (en) * | 1996-06-27 | 1998-02-17 | Bristol-Myers Squibb Company | Compositions and methods of treating HIV with d4T, 5-fluorouracil/tegafur, and uracil |
US6306909B1 (en) | 1997-03-12 | 2001-10-23 | Queen's University At Kingston | Anti-epileptogenic agents |
US6177437B1 (en) * | 1998-09-04 | 2001-01-23 | University Of Massachusetts Medical Center | Inhibitors of Herpes Simplex virus uracil-DNA glycosylase |
KR100814269B1 (ko) * | 2000-01-25 | 2008-03-18 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 고나도트로핀-분비 호르몬 수용체 길항제 및 이를 포함하는 약제학적 조성물 |
US7501429B2 (en) * | 2001-04-11 | 2009-03-10 | Queen's University At Kingston | Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents |
JP2004536071A (ja) * | 2001-05-25 | 2004-12-02 | クイーンズ ユニバーシティ アット キングストン | 複素環ベータアミノ酸およびそれらの抗癲癇誘発剤としての使用 |
US8592421B2 (en) * | 2003-08-04 | 2013-11-26 | Valery Khazhmuratovich Zhilov | Cyclic bioisosters of purine system derivatives and a pharmaceutical composition based thereon |
AU2005311730B2 (en) * | 2004-12-03 | 2011-11-17 | Adherex Technologies, Inc. | Methods for administering DPD inhibitors in combination with 5-FU and 5-FU prodrugs |
US20100158966A1 (en) * | 2005-05-24 | 2010-06-24 | Ted Reid | Selenium-based biocidal formulations and methods of use thereof |
US8236337B2 (en) * | 2005-05-24 | 2012-08-07 | Selenium, Ltd. | Anti-microbial orthodontic compositions and appliances and methods of production and use thereof |
WO2007008293A2 (en) * | 2005-05-24 | 2007-01-18 | Selenium, Ltd. | Selenium-based biocidal formulations and methods of use thereof |
US9370187B2 (en) | 2005-05-24 | 2016-06-21 | Selenium, Ltd. | Selenium-based biocidal formulations and methods of use thereof |
US20100158967A1 (en) * | 2005-05-24 | 2010-06-24 | Ted Reid | Selenium-based biocidal formulations and methods of use thereof |
WO2007024863A2 (en) | 2005-08-22 | 2007-03-01 | Melior Discovery, Inc. | Methods and formulations for modulating lyn kinase activity and treating related disorders |
KR20100014480A (ko) * | 2007-02-20 | 2010-02-10 | 멜리어 파마슈티칼스 아이, 인코포레이티드 | Lyn 키나제 활성제의 확인 방법 |
CA2693809A1 (en) * | 2007-07-23 | 2009-01-29 | Melior Discovery, Inc. | Methods of activating irs-1 and akt |
AU2009223453B2 (en) | 2008-03-03 | 2014-05-01 | Tosk, Inc. | Methotrexate adjuvants to reduce toxicity and methods for using the same |
US8552184B2 (en) * | 2008-07-03 | 2013-10-08 | Melior Pharmaceuticals I, Inc. | Compounds and methods for treating disorders related to glucose metabolism |
BR112012008951A2 (pt) * | 2009-10-14 | 2019-09-24 | Adherex Tech Inc | tratamento de neurotoxidez associada com combinações de 5-fu ou seus profármacos e inibidores de dpd |
WO2011150300A1 (en) | 2010-05-28 | 2011-12-01 | Melior Pharmaceuticals I, Inc. | Prevention of pancreatic beta cell degeneration |
CA3059432A1 (en) | 2017-04-10 | 2018-10-18 | Melior Pharmaceuticals I, Inc. | Compositions comprising a lyn kinase activator and a trpms agonist |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3755295A (en) * | 1969-10-24 | 1973-08-28 | Syntex Corp | 1-(2-amino-2-deoxy-{62 -d-ribofuranosyl) pyrimidines and derivatives thereof |
US3687931A (en) * | 1970-03-19 | 1972-08-29 | Syntex Corp | Halogenated purine and pyrimidine nucleosides and process therefor |
JPS5738774A (en) * | 1980-08-19 | 1982-03-03 | Chugai Pharmaceut Co Ltd | Uracil derivative and its preparation |
US4868187A (en) * | 1980-09-16 | 1989-09-19 | Syntex (U.S.A.) Inc. | Anti-viral N-substituted pyrimidines |
US4613604A (en) * | 1985-07-31 | 1986-09-23 | Brown University Research Foundation | Hydroxymethyl derivatives of 5-benzylacyclouridine and 5-benzoyloxybenzylacyclouridine and their use as potentiators for 5-fluoro-2'-deoxyuridine |
CA1334535C (en) * | 1988-03-31 | 1995-02-21 | Tadashi Miyasaka | 6-substituted acyclopyrimidine nucleoside derivative and antiviral agent containing the same as active ingredient thereof |
US5077280A (en) * | 1988-04-12 | 1991-12-31 | Brown University Research Foundation | Treatment of viral infections |
CA2039039C (en) * | 1990-03-29 | 2001-05-15 | Tadashi Miyasaka | Pyrimidine nucleoside derivative and antiviral agent containing the derivative as active ingredient |
US5141943A (en) * | 1990-04-12 | 1992-08-25 | Brown University Research Foundation | 5-benzyl barbiturate derivatives |
US5476855A (en) * | 1993-11-02 | 1995-12-19 | Mahmoud H. el Kouni | Enzyme inhibitors, their synthesis and methods for use |
KR0151811B1 (ko) * | 1993-12-21 | 1998-10-15 | 강박광 | 신규한 항바이러스성 2,4-피리미딘디온 유도체 및 그의 제조방법 |
-
1993
- 1993-11-02 US US08/146,838 patent/US5476855A/en not_active Ceased
-
1994
- 1994-09-30 JP JP51321195A patent/JP3621102B2/ja not_active Expired - Fee Related
- 1994-09-30 EP EP94929398A patent/EP0725641B1/en not_active Expired - Lifetime
- 1994-09-30 WO PCT/US1994/011173 patent/WO1995012400A1/en active IP Right Grant
- 1994-09-30 ES ES94929398T patent/ES2155093T3/es not_active Expired - Lifetime
- 1994-09-30 DE DE69426423T patent/DE69426423T2/de not_active Expired - Lifetime
- 1994-09-30 AU AU78476/94A patent/AU699914B2/en not_active Ceased
- 1994-09-30 AT AT94929398T patent/ATE198046T1/de not_active IP Right Cessation
- 1994-09-30 PT PT94929398T patent/PT725641E/pt unknown
-
1995
- 1995-06-06 US US08/466,470 patent/US5721241A/en not_active Expired - Lifetime
-
1997
- 1997-12-01 US US08/980,629 patent/USRE37623E1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US5721241A (en) | 1998-02-24 |
USRE37623E1 (en) | 2002-04-02 |
US5476855A (en) | 1995-12-19 |
WO1995012400A1 (en) | 1995-05-11 |
DE69426423T2 (de) | 2001-07-12 |
EP0725641A4 (ja) | 1996-09-04 |
PT725641E (pt) | 2001-05-31 |
EP0725641A1 (en) | 1996-08-14 |
EP0725641B1 (en) | 2000-12-13 |
DE69426423D1 (de) | 2001-01-18 |
AU699914B2 (en) | 1998-12-17 |
ATE198046T1 (de) | 2000-12-15 |
JP3621102B2 (ja) | 2005-02-16 |
ES2155093T3 (es) | 2001-05-01 |
AU7847694A (en) | 1995-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3621102B2 (ja) | 新規な酵素阻害剤、その合成及び使用方法 | |
US5141943A (en) | 5-benzyl barbiturate derivatives | |
KR100279953B1 (ko) | 항-b형 간염 바이러스제 및 항-사람 면역결핍 바이러스제로서의 l-2',3'-디데옥시 누클레오시드 유사체 | |
US5723449A (en) | Methods and compositions for inhibiting uridine secretion | |
Gerhart et al. | 2-(4-Amino-4-carboxybutyl) aziridine-2-carboxylic acid. A potent irreversible inhibitor of diaminopimelic acid epimerase. Spontaneous formation from. alpha.-(halomethyl) diaminopimelic acids | |
US6211166B1 (en) | 5′-deoxy-cytidine derivative administration to treat solid tumors | |
US6911450B1 (en) | Pyrimidine acyclonucleoside derivatives, preparation method and use thereof | |
DE69132052T2 (de) | Uracil-reductase-inaktivator | |
DE69128626T2 (de) | Enzyminaktivatoren | |
JPS6337766B2 (ja) | ||
CA2176720C (en) | Novel enzyme inhibitors, their synthesis, and methods for use | |
EP0290558A1 (en) | ANTIFOLATE AGENT. | |
JP2000516578A (ja) | アデノシンデアミナーゼ阻害剤 | |
US8349834B2 (en) | Dioxolane derivates for the treatment of cancer | |
RU2036909C1 (ru) | Ацилпроизводные гидроксипиримидинов | |
JPS6337787B2 (ja) | ||
US7999099B2 (en) | Modified 5′-phosphonate azidothymidine—potential anti-viral preparations | |
JPS6223723B2 (ja) | ||
JPH06172365A (ja) | 10−チアイソアロキサジン誘導体およびその用途 | |
JPH05178746A (ja) | 抗ウイルス剤 | |
JPS6223724B2 (ja) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040217 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040517 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040628 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040709 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20041019 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20041117 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081126 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091126 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091126 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101126 Year of fee payment: 6 |
|
LAPS | Cancellation because of no payment of annual fees |